Phoenix New Media Hong Kong stock | Sihuan Pharmaceutical (00460) announced that its Xuanzhu Biology has received an application from the Drug Evaluation Center of the State Drug Administration of China to conduct a phase III clinical trial of Pirozinib (Birociclib,XZP-3287 CDK4/6 (cell cycle dependent kinase 4 and 6) inhibitors) ("Pirosini"). The combination of pyrrosinil and aromatase inhibitors is used in locally advanced or metastatic breast cancer with hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-). In August 2021, the combination of Pirosinil and flurvist has been approved for phase III clinical trials.
【港股通】四环医药(00460)旗下轩竹生物吡罗西尼获批开展三期临床试验
[Hong Kong Stock Exchange] Pirosini, a subsidiary of Sihuan Medicine (00460), has been approved to carry out phase III clinical trials.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.